Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Delphax Technologies, Inc.

<u>12301 Whitewater Drive, Suite 10</u> <u>Minnetonka, MN 55343</u>

(952)829-5700

<u>Quarterly</u> Report For the Period Ending: <u>December 31, 2020</u> (the "Reporting Period")

As of <u>December 31, 2020</u>, the number of shares outstanding of our Common Stock was:

6,919,465

As of September 30, 2020, the number of shares outstanding of our Common Stock was:

6,919,465

As of September 30, 2020, the number of shares outstanding of our Common Stock was:

6,919,465

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: □ No: ⊠

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: \Box No: \boxtimes

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: □ No: ⊠

1) Name and address(es) of the issuer and its predecessors (if any)

¹ "Change in Control" shall mean any events resulting in:

⁽i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

⁽ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

⁽iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

⁽iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Delphax Technologies, Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Minnesota -active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

<u>12301 Whitewater Drive, Suite 10</u> <u>Minnetonka, MN 55343</u>

The address(es) of the issuer's principal place of business: Check box if principal executive office and principal place of business are the same address: \square

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: □ No: ⊠

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

<u>N/A</u>

2) Security Information

Trading symbol:	<u>DLPX</u>
Exact title and class of securities outstanding:	Common stock
CUSIP:	24712X106
Par or stated value:	<u>\$0.10 per share</u>
Total shares authorized:	50,000,000 as of date: December 31, 2020
Total shares outstanding:	6,919,465 as of date: December 31, 2020
Number of shares in the Public Float ² :	6,919,465 as of date: December 31, 2020
Total number of shareholders of record:	225 as of date: <u>December 31, 2020</u>
Exact title and class of securities outstanding: CUSIP: Par or stated value: Total shares authorized: Total shares outstanding: Number of shares in the Public Float ² :	Common stock 24712X106 <u>\$0.10 per share</u> <u>50,000,000</u> as of date: December 31, 2020 <u>6,919,465 as</u> of date: December 31, 2020 6,919,465 as of date: December 31, 2020

² "Public Float" shall mean the total number of un restricted shares not held directly or indirectly by an officer, director, an y person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

All additional class(es) of publicly traded securities (if any):

Trading symbol:	<u>N/A</u>
Exact title and class of securities outstanding:	Series B Preferred Stock
CUSIP:	<u>N/A</u>
Par or stated value:	<u>\$0.10 per share</u>
Total shares authorized:	43,000 as of date: December 31, 2020
Total shares outstanding:	43,000 as of date: December 31, 2020

Transfer Agent

Name:	Equiniti Trust Company
Phone:	(651) 450-4137
Email:	mteam@equiniti.com
Address:	1110 Centre Pointe Curve, Suite 101
	Mendota Heights, MN 55120

Is the Transfer Agent registered under the Exchange Act?³ Yes: \square No: \square

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Shares Outstandin Fiscal Year End: Date <u>09/30/2019</u>	<u>Opening</u> Common	Most Recent <u>Balance</u> 1: <u>6,919,465</u> d: <u>43,000</u>		*Right	t-click the row	<i>i</i> s below and select	"Insert" to add rows	as needed.	
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstandin	g on Date of Thi	is Report:				
Ending Balance:	<u>Ending</u>	Balance				
Date <u>9/30/2020</u>	Commor	n: <u>6,919,465</u>				
	Preferred	: <u>43,000</u>				

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

Notes:

On October 2, 2015, for \$1,050,000, the Company issued 43,000 shares of Series B Preferred Stock and a Stock Purchase Warrant to sell an additional 95,600 shares of Series B Preferred Stock. The Series B Preferred Stock was a new series of preferred stock of Delphax. Each share of Series B Preferred Stock is convertible into 100 shares of Delphax common stock. Shares of Series B Preferred Stock may be converted at any time at the election of the holder thereof into shares of common stock of Delphax upon the written consent of the holders of a majority of the thenoutstanding shares of Series B Preferred Stock or in connection with the consummation of a registered underwritten public offering of Delphax common stock that satisfies specified aggregate offering and price thresholds. Based on the number of shares of Delphax common stock currently outstanding, the Series B Preferred Stock, if fully converted, would represent approximately 38.3% of the shares of Delphax common stock and the Warrants, if fully converted, would represent approximately 66.7% of the shares of Delphax common stock.

The Warrant is transferable and may be exercised in whole or in part at any time or times prior to its expiration on November 24, 2021. The Warrant provides that, prior to any exercise of the Warrant, the Holder must first make a good faith written tender offer to existing holders of Delphax common stock to purchase an aggregate amount of common stock equal to the number of shares of common stock issuable upon conversion of the Series B Preferred Stock that would be purchased upon such exercise of the Warrant. The Warrant requires that the per share purchase price to be offered in such tender offer would be equal to the then-current exercise price of the Warrant divided by the then-current conversion rate of the Series B Preferred Stock. To the extent that shares of common stock are purchased by the holder in the tender offer, the amount of shares of Series B Preferred Stock purchasable under the Warrant held by such holder is to be ratably reduced. The Warrant, which has a full ratchet feature, is to be exercised for cash, by surrender of a portion of the Warrant having a value equal to the aggregate exercise price based on the difference between the Warrant exercise price per share and an average market value, measured over a 20-trading day period of Delphax common stock that would be acquired upon conversion of one share of Series B Preferred Stock.

As of December 31, 2020, a total of 891,000 options to purchase common stock of the Company were outstanding and exercisable. Of this total, 540,000 with an exercise price of \$0.47 are due to expire 2/28/21; 40,000 with an exercise price of \$0.50 are due to expire 4/15/21; 15,000 with an exercise price of \$0.36 per share are scheduled to expire on August 28, 2021. The remaining 296,000 have an exercise price of \$0.43 per share and are scheduled to expire on January 9, 2022. No options were exercised during the period presented.

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
					·		

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

⊠ U.S. GAAP □ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

 Name:
 Rodney Peterson

 Title:
 CEO

 Relationship to Issuer:
 Notes: The financials were compiled from advice and counsel of several financial advisors.

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company is in the business of leasing its patents and trademarks to third party commercial printer manufacturers

- B. Please list any subsidiaries, parents, or affiliated companies. The issuer had three subsidiaries, all of which have been dissolved through bankruptcy or struck from the record/register:
 - 1.) Delphax Technologies SAS (France): liquidated and struck off the register as of 10/24/2019
 - 2.) Delphax Canada Ltd. (Canada): dissolved through bankruptcy as of 6/30/2019
 - 3.) Delphax Technologies Ltd. (UK): liquidated and struck off the record as of 6/11/2019

The related assets and liabilities of Delphax Technologies Ltd and Delphax Canada Ltd were written off the lssuer's financials during the quarter ending 6/30/2019. The related assets and liabilities for Delphax Technologies SAS were written off the lssuer's financials during the fiscal year ending 9/30/2020.

C. Describe the issuers' principal products or services.

The Issuer is in the business of leasing its patents and trademarks to third party commercial printer manufacturers.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Issuer leases space from a third-party vendor. The Issuer also contracts with third party consultants in order to save resources.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Air T, Inc.</u>	<u>The entity owns</u> <u>Series B</u> <u>Preferred stock</u>	<u>Minneapolis, MN</u>	<u>43,000</u>	<u>Series B</u> <u>Preferred</u> <u>Stock</u>	<u>100%</u>	<u>See section 3</u> <u>Notes</u>
Nick Swenson	Board member	<u>Minneapolis, MN</u>				
Michael Moore	<u>Chairman</u>	<u>Minneapolis, MN</u>				
Rodney Peterson	<u>CEO</u>	<u>Minneapolis, MN</u>				
Patrick Brennan	<u>Co-CEO</u>	<u>Minneapolis, MN</u>				

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

<u>None</u>

 The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

<u>None</u>

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name:	Matthew J. Borger
Firm:	Noone & Borger, LLC.
Address 1:	32 South Church Street
Address 2:	West Chester, PA 19382
Phone:	<u>(484) 947-5383</u>
Email:	matt@nooneborger.com

Accountant or Auditor

Name: Firm: Address 1: Address 2: Phone: Email:	
Investor Relations	
Name: Firm:	<u>None</u>

Name.	<u>INOTIC</u>
Firm:	
Address 1:	
Address 2:	

OTC Markets Group Inc.

Phone: Email:

Other Service Providers

Provide the name of any other service provider(s) that **that assisted**, **advised**, **prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period. Name:

Firm: Nature of Services: Address 1: Address 2: Phone: Email:

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, <u>Rodney Peterson</u> certify that:

1. I have reviewed this <u>Quarterly Disclosure</u> of Delphax Technologies, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 30, 2021 [Date]

<u>/s/Rodney Peterson</u> [CEO's Signature] (Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Rodney Peterson certify that:

1. I have reviewed this guarterly disclosure of Delphax Technologies, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 30, 2021 [Date] /s/Rodney Peterson [CFO's Signature] (Digital Signatures should appear as "/s/[OFFICER NAME]")

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS For The Period Ended December 31, 2020

NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

The Company:

Delphax Technologies, Inc. is in the business of leasing its patents and trademarks to third party commercial printer manufacturers.

Basis of Presentation

The unaudited consolidated financial statements of the Company have been prepared in accordance with the U.S. Generally Accepted Accounting Principles ("U.S. GAAP").

Item 2 Cash and Cash Equivalents

There has been minimal change in our cash or cash equivalents. Our operating cash bank accounts are FDIC insured.

Item 3 Accounts Receivable

The accounts receivable balances are generated primarily from patent agreements.

Item 4 Accounts Payable

The accounts payable balances include third party fulfillment charges, storage charges and related outside services.

Item 5 Other Information

The company maintains a September 30 fiscal year end. Included in the deferred tax balances are U.S. federal and state loss carryforwards of \$14.5 million and \$24.0 million, respectively. The net operating losses expire in varying amounts beginning in the tax year 2028.

The provisions of ASC 740 require an assessment of both positive and negative evidence when determining whether it is more-likely-than-not that deferred tax assets will be recovered. In accounting for the Companies tax attributes, the Company has established a full valuation allowance of \$3.05 million. The cumulative tax losses incurred by the Company in recent years was the primary basis for the Company's determination that a full valuation allowance should be established against the Companies' net deferred tax assets.

Delphax Technologies, Inc. Balance Sheet Comparison As of December 31, 2020

	December 31, 2020	September 30, 2020
ASSETS		
Current Assets:		
Cash and cash equivalents	1,304	2,353
Accounts Receivable, net	67,844	64,844
Other current assets		-
Total current assets	69,148	67,197
Total Assets	69,148	67,197
LIABILITIES		
Current Liabilities		
	43,096	20,406
Accounts Payable	45,090	39,496
Accrued Expenses	-	-
Total current liabilities	43,096	39,496
Total Liabilities	43,096	39,496
STOCKHOLDERS EQUITY		
Common Stock	691,947	691,947
Preferred Stock	4,300	4,300
Additional Paid In Capital	24,600,965	24,595,965
Accumulative Deficit	(25,271,160)	(25,264,511)
Other Comprehensive Income	-	-
Total stockholders equity	26,052	27,701
Total Liabilities and Stockholders equity	69,148	67,197

Delphax Technologies, Inc. Profit and Loss As of December 31, 2020

	Three Months Ended December 31,
	2020
Operating Revenues	-
Operating Expenses: Cost of sales	
General and adminstrative	9,649 9,649
Operating Loss	(9,649)
Gain/Loss on Extinguishment o	of Debt
Other Non-operating Income (Expenses), <u>3,000</u>
Income (Loss) Before Income T	axes (6,649)
Income Taxes	-
Net Income (Loss)	(6,649)

Delphax Technologies, Inc. Statement of Cash Flows As of December 31, 2020

	Three Months Ended December 31, 2020		
	December 51, 2020		
Net Income	(6,649)		
Adjustments to Net Income			
Increase in Accounts Receivable	(3,000)		
Increase in Accounts Payable	3,600		
Net Cash Provided by Operating Activities	(6,049)		
Cash Flow from Financing Activities			
Shareholder Contributions	5,000		
Net Cash provided by Financing Activities	5,000		
Increase/Decrease in Cash Flow	(1,049)		
Cash and Cash Equivalents 09.30.20	2,353		
Cash and Cash Equivalents 12.31.20	1,304		

Delphax Technologies, Inc. Consolidated Statement of Changes in Stockholders' Deficit As of December 31, 2020 Unaudited

onducticu						
				Other		
			Additional Paid In	Comprehensive	Accumulated	
	Common Stock	Preferred Stock	Capial	Income (OCI)	Deficit	Total
09.30.18 Balance	691,947	4,300	24,450,965	(1,146,004)	(29,970,282)	(5,969,075)
Net Income					5,521,094	5,521,094
Deconsolidation of Subsidiary Impact on OCI				537,882	(537,882)	-
Shareholder Capital			41,500			41,500
09.30.19 Balance	691,947	4,300	24,492,465	(608,122)	(24,987,070)	(406,480)
Net Income					330,681	330,681
Deconsolidation of Subsidiary Impact on OCI				608,122	(608,122)	
Shareholder Capital			103,500			103,500
09.30.20 Balance	691,947	4,300	24,595,965	-	(25,264,511)	27,701
Net Income					(6,649)	(6,649)
Shareholder Capital			5,000			5,000
12.31.20 Balance	691,947	4,300	24,600,965	-	(25,271,160)	26,051